The UK is going to be at a distinct disadvantage in this negotiation – desperate for a deal the US could happily live without.

A US-UK trade deal is being negotiated, and drug prices are a key issue. Several US officials are demanding that foreign countries pay higher prices to US drug companies.

NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Experts from ICON give us their views on the past, present and future of NICE’s standing on the world stage.

George Hollingbery, then trade minister, and John Saville, Her Majesty’s Consul General in Chicago met a pharmaceutical company's senior director in August last year to discuss a post-Brexit pact.

For almost 50 years, the NHS benefited from easy access to a large market, meaning it’s been first in the queue for the latest innovations. But what impact might Brexit have on medicines, medical devices and life sciences in the UK? Mark Dayan explains, in a blog that was first published in the BMJ on 26 February.

Asked if Washington would be free to ‘jack up prices’, Foreign Secretary Dominic Raab replies ‘The Americans will take their decisions’.

President will put US firms first in UK trade talks, says Kim Darroch

'What they will actually target is the process by which we control pharmaceutical pricing. That is where they will be pushing - we have to resist them'

Fears extra expense and paperwork caused by Brexit will make Britain unattractive to global drugmakers.

Global issues are factor but experts say there are problems peculiar to Britain such as rising costs post-Brexit.